Clinical trials: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Condition Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Funder type Industry (pharma, biotech, devices)
Brain Metastases From Non-small Cell Lung Cancer
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT01657799
- Testing
- Veliparib, Whole brain radiation therapy
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer.
- Trial name
- NCT00415363
- Testing
- enzastaurin
- Where
- 7 sites in Denmark, Norway and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms
- Trial name
- NCT00076856
- Testing
- Temozolomide
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Non-Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain.
- Trial name
- NCT00390806
- Testing
- HYCAMTIN, oral capsules, Radiation
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Metastatic Non-Small Cell Lung Cancer
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases
This is a randomized, Phase II study designed to investigate Nimotuzumab plus whole-brain radiation therapy (WBRT)and to compare it rith WBRT alone in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT00872482
- Testing
- nimotuzumab
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- YM BioSciences
Brain Metastases, Lung Cancer Metastatic
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer…
- Conditions
- Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- NCT03638765
- Testing
- DCVax-Direct
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwest Biotherapeutics
1-5 Brain Metastases From Non-Small Cell Lung Cancer
Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
The study is a prospective, randomly controlled phase II trial, designed to test the efficacy, safety and neurocognitive outcomes of a medical device, the NovoTTF-100A, in the treatment of NSCLC patients with controlled systemic…
- Trial name
- NCT01755624
- Testing
- NovoTTF-100A device, Best Standard of Care
- Where
- 7 sites in Czechia, France and 3 more
- Volunteers
- 18 people
- Sponsor
- NovoCure Ltd.
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
NSCLC Brain Metastasis
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the…
- Trial name
- NCT06716775
- Testing
- Tumor treating felds (TTF), Best Standard of Care
- Volunteers
- 200 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually. Nonsmall cell lung cancer accounts for the majority of CNS mets.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
- Trial name
- NCT00034697
- Testing
- temozolomide
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis…
- Trial name
- NCT02831959
- Testing
- NovoTTF-200M device, Best Standard of Care
- Where
- 128 sites in United States, Austria and 13 more
- Volunteers
- 298 people
- Sponsor
- NovoCure GmbH
Brain Metastasis, Non-small Cell Lung Cancer
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after…
- Trial name
- NCT00219297
- Testing
- Patupilone
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals